Infection and Vaccines

Addressing infectious diseases

Jump to section:

AstraZeneca is committed to developing and implementing scientific advancement in infection and vaccines.

We work to protect patients against the burden of influenza, respiratory syncytial virus (RSV) and bacterial infections, particularly those resistant to current antibiotics.

In Europe, antimicrobial resistance results in 25,000 deaths from hospital-acquired infections, while there are 3-5 million severe cases of influenza each year worldwide. RSV disease is the leading cause of hospitalisation in children under one year of age in the United States

Demand for health interventions to address these burdens of disease remains high and, through working with the wider infection community, AstraZeneca aims to translate science into solutions to address global challenges faced in these disease areas.

Our focus on infectious diseases

Infectious diseases are the second-leading cause of death worldwide, after heart disease, and are responsible for more deaths annually than cancer.

  • Antimicrobial resistance (AMR)

    AMR is a major public health threat. As bacteria develop resistance to current antibiotics, deadly infections could, again, become uncontrollable.

  • Seasonal influenza

    Seasonal influenza is a serious public health problem that causes severe illness and death in high-risk populations.

25,000

In Europe alone, AMR causes 25,000 deaths every year; two thirds of these are due to Gram-negative bacteria.

1.5 billion

AMR will result in 1.5 billion EUR extra healthcare costs and productivity losses across Europe, based on 2007 estimates.

1 billion

There are an estimated 1 billion cases of influenza each year worldwide.

300,000-500,000

Each year there are around 300,000-500,000 deaths due to influenza worldwide.

Our pipeline

We have an exciting and balanced pipeline underpinned by great science.

View Pipeline

Our medicines

We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations. Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.

Find your country site in the AZ Network

Synagis 

palivizumab

Fluenz Tetra/FluMist Quadrivalent

influenza vaccine live, intra-nasal

Resources

Sharing clinical trials information

We publish information about the registration and results of all new and ongoing clinical trials for all products in all phases on our dedicated website.

Information about our medicines

Our medicines are approved in individual countries for specific uses. Visit your local AstraZeneca site to find out more

Latest news

Evusheld long-acting antibody combination retains neutralising activity against Omicron variants BA.4 and BA.5, according to new study from University of Oxford

Vaxzevria approved in the EU as third dose booster against COVID-19

  • Corporate Press Release

New Vaxzevria data further support its use as third dose booster

  • Corporate Press Release

Two of our employees recognised in The Queen’s New Year’s Honours for their outstanding achievements in life sciences during the pandemic

Vaxzevria significantly boosted antibody levels against Omicron

  • Corporate Press Release

Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in studies from Oxford and Washington Universities

  • Corporate Press Release
View all news and press releases